NIGMS Maximizing Investigators' Research Award (MIRA) for Early Stage Investigators (PAR-27-032)

NIGMS Maximizing Investigators’ Research Award (MIRA) for Early Stage Investigators (PAR-27-032)

For early-stage biomedical investigators trying to scale independent programs after launch, PAR-27-032 is one of the most strategically useful U.S. federal opportunities currently open in 2026 and 2027. It is a notice-of-funding-opportunity (NOFO) pathway for the Maximizing Investigators’ Research Award (MIRA) with an R35 mechanism and Clinical Trial: Optional. Unlike many NIH awards that expect a tightly bounded hypothesis set, this program is designed around a broader program of research that fits the National Institute of General Medical Sciences (NIGMS) mission.

What sets this opportunity apart is its explicit purpose: stabilize a promising early-stage laboratory and reduce short-term grant churn. The NOFO states that MIRA support is intended to give investigators greater flexibility, improve reliability of support, and increase scientific productivity across research teams. The model is not meant to fund a single narrow objective and then stop; it supports a research program, sustained by the principal investigator, over multiple years.

Because you asked for strong opportunities in 2026 and 2027, this is especially relevant: this NOFO is posted in 2026 with recurring rounds through 2029, and has active 2026/2027 due dates for applications. That makes it a practical monitoring and planning target for both current and near-term cycles.

Key details at a glance

What this opportunity is (and is not)

The opportunity is aimed at researchers at the early-stage investigator stage who already have a program direction, not just one pilot experiment. In practical terms, this NOFO is usually worth more than short-cycle project grants because it supports research breadth within a lab-level program as long as it remains within NIGMS mission boundaries.

It is especially useful when your team can explain that your science has multiple active streams that reinforce each other and need stable funding to progress together. This is often a better fit than an R01 route if your early-stage program requires pivots in methods, new directions, or coordinated work across several sub-questions. MIRA’s design is to tolerate some exploration while still keeping reviewer expectations around mission relevance and feasibility high.

It is not a mechanism for everything that can be described as biomedical. The NOFO explicitly says applications outside the NIGMS mission are returned without review. So your first checkpoint is not whether you need funding, but whether your core mission is firmly in NIGMS-funded domains: foundational biological questions that support broader understanding and downstream advances in medicine.

Another practical distinction: this is not a consortium grant mechanism and does not permit multiple PI applications. You should treat the program as single PI-driven leadership with collaborators and networks, not a multi-PI vehicle.

The award is not “preliminary data only” friendly in the traditional sense. In this model, applicants are encouraged to propose broader long-term scientific direction rather than overfitting to a single set of experiments that only works if preliminary results are already strong. The NOFO and associated NIGMS FAQ repeatedly reinforce that this program has different scoring priorities than classical project grants.

Who can apply: the full eligibility shape

The easiest mistake is to treat this as a narrow PI-only filter. In fact, the NOFO includes a broad list of eligible applicant organizations:

• Public and private institutions of higher education.
• Nonprofits with and without 501(c)(3) status.
• For-profit organizations, including small businesses.
• Local governments, federal agencies, independent school districts, public and Indian housing authorities, tribal organizations, and some regional/faith/community-type organizations.

However, there is an important boundary: foreign institutions are not eligible applicants. Foreign components can be allowed in certain cases, but not foreign U.S. component entities in the standard sense that disqualify the base eligibility.

At the PI level, the NOFO limits to NIH-defined ESIs. The review team checks ESI status at submission time. If your ESI status is not confirmed, your application can fail before meaningful scientific review. If you are a New Investigator but not ESI, this is the wrong NOFO.

The PI must be single and must commit at least 51% of total research effort to the award. This requirement is not optional language. It is enforced through effort accounting in other support materials and Just-In-Time (JIT) review.

Ineligibility filters that often catch strong teams:

• PD/PI not ESI at submission.
• Any PI with PI-level concurrent NIGMS research applications still under review in overlapping conflicts the NOFO forbids.
• Multiple PI applications.
• Applications outside the mission.

For teams with collaborators, remember that MIRA centers on investigator autonomy, not a full consortium grant architecture. You can involve collaborators, but you must still frame the submission as one PI-driven program.

Why this is useful for 2026/2027 planning cycles

The NOFO lists explicit recurring cycles and is not a one-off call:

• 2026: October 2
• 2027: February 3 and October 4
• 2028: February 3 and October 3
• 2029: February 6

For planning in your 2026–2027 window, the immediate value is:

1. There is a known opening date: September 2, 2026.
2. The first 2026 and 2027 opportunities are fully posted with defined key milestones.
3. If you miss early windows, the 2027 dates remain open if your team’s timeline permits.
4. Review and award pathways are staged, so you can budget to an internal cycle:
   • application due
   • peer review
   • council review
   • earliest possible start

The table in the NOFO maps these to March/May and July starts in the 2026/2027 cycle, with additional cycles in later years. In short, this is the kind of NOFO where missing the current cycle is recoverable as long as your team stays ready for the next submission date and keeps ESI status current.

Funding structure and submission mechanics

The funding cap is straightforward to communicate internally:

• Up to $275,000 direct costs per year.
• Up to 5 years in 12-month budget periods.
• No requested cost sharing or matching funding.
• No consortium/subcontract allowed for collaborators; no foreign subawards.

Budget submissions should not include an overly granular itemized format. Per the NIGMS guidance, you provide a total budget request in the format expected by the NOFO and include budget justification for required categories.

Critical submission rules:

• No specific aims section language is expected in the same way as other NIH applications. The NOFO repeatedly warns against “specific aims” sections or similar headings in abstract/research strategy.
• Institutional letter of support from chair/dean or equivalent is required, covering institutional commitment, startup support, space, mentoring, and tenure/promotion context.
• Applications are due at 5:00 PM local time on the due date.
• This NOFO allows application types of new and revision only; resubmissions are not accepted under the same NOFO framework.

The application cannot rely on preliminary data as the single argument for potential. Early-stage applicants are explicitly allowed to propose broader ideas without overdependence on a fixed pre-study result history. That does not mean weak science; it means the reviewer should see a durable research trajectory and a feasible program design.

Before application: prep checklist by function

1) Eligibility and PI readiness

• Confirm ESI status against current NIH definitions and recent extension policies.
• Verify no other prohibited overlapping application conflicts exist under NIH peer review rules.
• Confirm your institution’s registration status (SAM, UEI, Grants.gov, eRA Commons) is active.
• Confirm the PD/PI research effort model at submission.

The NIGMS team explicitly expects only one PD/PI, so avoid late structure changes that introduce co-PIs.

2) Program alignment

Build an “in scope/in mission” argument that goes deeper than one paragraph:

• Which NIGMS mission areas you address.
• How the program’s biological questions are foundational or mechanism-oriented.
• What scientific outcomes could plausibly shift a broader field, not just one niche output.

The NOFO reviewers are instructed to judge the research program and not micro-level narrow experimental detail. The highest quality applications do this by providing a coherent story about program-level direction.

3) Drafting the research strategy

Because this is a program-style award, structure should do the following:

• Explain how multiple project threads connect.
• Show why flexibility is needed and how it improves risk profile.
• Avoid “specific aims” formatting; present the science as a sustained program with clear rationale.
• Show resource leverage and trainee mentoring plans.

The application should also include realistic, operational sections around human subjects, vertebrate animals, authentication of key resources, data management and sharing, and resource-sharing plans.

4) Budget and justification

Use one annual total request and clear justifications:

• Direct costs up to the cap.
• No inflation escalation.
• Equipment is allowed with justification and can include first-year and later year requests.
• Data management and sharing should be explicitly costed only as needed, with a capped plan.

Foreign components are policy-defined and must be justified through standard channels.

5) Timing strategy for two-cycle planning

If aiming for 2027 opportunities, work backward from the February date:

• T-16 weeks: confirm eligibility, ESI status, organization registration, and NIGMS alignment.
• T-12 weeks: finalize program description and effort allocations.
• T-8 weeks: draft full forms, letters of commitment, and budget package.
• T-4 weeks: conduct internal compliance pre-check against NOFO response criteria.
• T-2 weeks: verify attachments and portal workflow (Grants.gov/S2S).
• T-2 days: submit and confirm final status before deadline.

This pipeline is conservative but realistic. NIH deadlines are unforgiving for missing required documents and late registration checks.

Review logic and how to increase acceptance probability

Review for PAR-27-032 is structured like other NIH merit review, but with a strong focus on the investigator’s ability to maintain a durable, high-impact program in the NIGMS mission area.

The NOFO says reviewers are focused on:

• Program significance and potential impact.
• Approach as a broad program, not narrow experiment-by-experiment optimization.
• Investigator productivity and scientific impact relative to career stage.
• Environment and trainee plan, including mentoring context.
• Budget reasonableness.

Important practical point: if your proposal is method-rich but weak on program coherence, it loses on this mechanism. If it is coherent but vague, it also loses. The successful narrative is specific enough to show rigorous execution but broad enough to show why the program deserves multi-year stability.

Use the review perspective as a decision frame:

1. What is the scientific problem class?
2. Why does this investigator need multi-year flexibility?
3. Why is this not just one R01-style pilot extension?
4. Is the project truly within NIGMS mission boundaries?
5. Are administrative/compliance requirements handled with no ambiguity?

If you can answer those clearly and internally consistently, you align with the NOFO’s scoring culture.

Common mistakes to avoid

1. Using forbidden “specific aims” structure. The NOFO explicitly flags this as non-responsive.

2. Applying with a non-ESI PI. Even a technically strong science proposal can be withdrawn without review.

3. Underestimating the effort requirement. The PI 51% research effort requirement is a hard rule.

4. Assuming preliminary data dominance. Strong conceptual and program-level framing matters more than overfit data depth.

5. Letting registration drift. SAM, Grants.gov, and eRA Commons must be active at submission.

6. Submitting a multi-PI application when the NOFO expects single-PD/PI. This is not the right instrument for shared PI models.

7. Not including institutional support documentation. Missing letters can create a hard rejection.

Practical FAQ for teams evaluating this now

Does this require preliminary data?

No. NIH language for this opportunity does not require preliminary data in the same way some highly specific R-series opportunities do. You should still show feasibility, but you are not judged primarily on short-run evidence accumulation.

Can small businesses apply?

Yes, if other NOFO and NIH PI/eligibility conditions are met.

Is this for international institutions?

Foreign institutions themselves are not eligible applicants in this NOFO. Foreign collaboration components may be allowed, but treatment follows NIH policy and the NOFO’s specific provisions.

Are clinical trials allowed?

Clinical trials are optional. Mechanistic clinical studies within relevant NIGMS mission areas are permitted, while phase I–III trials for future regulatory approval are outside scope.

Can I apply again after rejection?

Resubmissions to the same NOFO are not allowed, but a new application is possible after receiving the summary statement and if the PI remains eligible as an ESI.

What is the best way to sequence submissions?

Target one of the official windows, not both blindly. A first strong submission in 2026/early 2027 can often improve the next cycle if eligibility and feedback are maintained.

Official links and monitoring points

Keep this short and authoritative checklist:

• Official NIGMS opportunity record: https://simpler.grants.gov/opportunity/9a4aeb2f-d0ac-403b-ac67-9d1fd24d9556
• Official full announcement PDF (definitive NOFO): https://files.simpler.grants.gov/opportunities/9a4aeb2f-d0ac-403b-ac67-9d1fd24d9556/attachments/2037e87d-aae5-4621-8e37-b3fb158c3c26/PAR-27-032-Full-Announcement.pdf
• NIGMS MIRA overview and ESI FAQ page: https://www.nigms.nih.gov/Research/mechanisms/MIRA/Pages/default and https://www.nigms.nih.gov/Research/mechanisms/MIRA/Pages/faqs-esi-mira

For planning teams, treat the NOFO PDF as the primary requirement source, then use the NIGMS pages for practical implementation and interpretation.